Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04189783 · ClinicalTrials.gov registry record · Phase 2

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

A Phase 2 study of Retroperitoneal Sarcoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
113
Enrollment target
1
Study location

NCT04189783: Active Phase 2 study of Retroperitoneal Sarcoma, sponsored by M.D. Anderson Cancer Center.

NCT04189783 is a Phase 2 study of Retroperitoneal Sarcoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 113 participants, below the 397-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04189783, a Phase 2 study of Retroperitoneal Sarcoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
113 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decrease dependency on opioid medications for pain relief after surgery and prevent long-term use and addiction.

Primary Outcome

After sarcoma surgery, our historical discharge opioid prescription was a median of 300mg oral morphine equivalents (OME) in 2016-2018, with 5% patients discharged opioid-free. The primary objective of this study was to compare 2 novel opioid-reduction bundles to increase the proportion of opioid-free patients.

Conditions Studied

Interventions

  • OTHER Questionnaire Administration
  • DRUG Liposomal Bupivacaine
  • DRUG Quadratus Lumborum Block

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2020-06-08
Est. Completion 2026-12-31
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT04189783 still lists

NCT04189783 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 397-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Retroperitoneal Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.

NCT04189783 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04189783 about?

NCT04189783 is a clinical study titled "Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)". This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decreas...

What is the current status of trial NCT04189783?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2020-06-08. Estimated completion is 2026-12-31.

What conditions does trial NCT04189783 study?

This clinical trial studies the following conditions: Retroperitoneal Sarcoma.

What interventions are being tested in trial NCT04189783?

The interventions under investigation include: Questionnaire Administration (OTHER), Liposomal Bupivacaine (DRUG), Quadratus Lumborum Block (DRUG).

Who is sponsoring clinical trial NCT04189783?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04189783 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Retroperitoneal Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00748254 · 113 participants

    Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis

  • NCT04753190 · 113 participants · NA

    Light Timing Study

  • NCT05799248 · 113 participants · Phase 3

    Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

  • NCT07216105 · 113 participants · Phase 1

    FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04189783, the US trial registry maintained by the National Library of Medicine. NCT04189783 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.